IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2010;3(4):408-415

Original Article
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis
in a human neuroblastoma cell line

Hong Chai, Annie Z. Luo, Priya Weerasinghe, Robert E. Brown

Department of Pathology and Laboratory Medicine, University of Texas Health Science Center-Medical School at Houston, 6431 Fannin Street,
MSB 2.286, Houston, TX 77030, USA

Received March 29, 2010, accepted April 15, 2010, available online April 23, 2010

Abstract: Neuroblastoma is a common solid tumor in children and its tumorigenicity is enhanced by the expression of survival pathways such
as Akt and signal transducer and activator of transcription 3 (STAT3). Sorafenib is a multikinase inhibitor that also inhibits STAT3 signaling and
induces apoptosis. In this study, we will examine the efficacy of sorafenib on a human neuroblastoma cell line (SK-N-AS) and also investigate
its possible mechanisms. After cells reached 50-60% confluence, they were treated with various concentrations of sorafenib (0, 0.1, 1, 5, 10
and 20 μM) for different periods of time. The cell viability and apoptosis were determined by MTS colorimetric assay and TUNEL, respectively.
Phosphorylation of Akt1/2/3 (p-Akt1/2/3), extracellular signal-regulated kinase 1/2 (p-ERK1/2), STAT3 (p-STAT3), and AMP-activated protein
kinase alpha subunit (p-AMPKα) were determined with Western blot. The results indicate that as early as 2 hours post-treatment, cell viability
was significantly decreased at 10 μM concentration. In 24 hours or longer treatment groups, sorafenib at 5 μM and above significantly
decreased cell viability. TUNEL assay showed a significant increased of apoptosis in 5 and 20 μM treatment groups 24 hours after treatment.
Western blots showed a decrease of p-ERK1/2, p-Akt1/2/3, p-STAT3, and p-AMPKα expression levels in various sorafenib treatment groups.
Our results indicate that sorafenib significantly decreased cell viability and increased apoptosis in human neuroblastoma cell line in
association with down-regulation of p-ERK1/2, p-Akt, p-STAT3 survival pathways. These data suggested potential clinical application of
sorafenib in the treatment of neuroblastoma.(IJCEP10030011).

Key words: Neuroblastoma; Sorafenib; Apoptosis; Akt1/2/3 Protein Kinase; Signal Transducer and Activator of Transcription 3

Full text PDF

Address all correspondence to:
Robert E. Brown, MD
Department of Pathology and Laboratory Medicine
University of Texas Health Science Center- Medical School at Houston
6431 Fannin Street, MSB 2.286
Houston, TX 77030, USA.
Tel: (713) 500-5332
Fax: (713) 500-0695
E-mail:
robert.brown@uth.tmc.edu